#eddingpharm

1 story

#colorectal cancer #finance #gb268 #immunotherapy #markets #nmpa #phase 2 trial #pmmr/mss

Eddingpharm's GB268 Trial Approved in China
China's NMPA clears Eddingpharm's GB268 Phase 2 colorectal cancer trial.
BigGo Finance · 1m